GlassScriptPhysician profile
Marcos A Madeiro
NPI 1205092681
$2,410.54
in general payments reported to CMS, 2019-2025
22 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $285 · 2021: $321 · 2022: $156 · 2023: $409 · 2024: $355 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $406.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $337.81 | 2019-2024 | Xarelto |
| Pfizer INC. | $283.55 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $283.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $269.16 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $163.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.95 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $133.02 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.29 | 2020-2025 | Lifevest |
| Neurelis, INC. | $55.22 | 2023-2025 | Valtoco |
| Melinta Therapeutics, LLC | $45.05 | 2019-2021 | |
| Novo Nordisk INC | $40.59 | 2019 | |
| Advanced Respiratory, INC | $29.73 | 2019 | |
| Nestle Healthcare Nutrition INC. | $24.77 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $23.97 | 2024 | Ultomiris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $18.28 | 2025 | Yupelri |
| Vyera Pharmaceuticals, LLC | $17.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.51 | 2023 | |
| Boston Scientific Corporation | $17.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2023 | |
| Madrigal Pharmaceuticals | $17.12 | 2024 | Resmetirom |
| Ekos Corporation | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Madeiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.